# HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

> **NCT05787535** · PHASE1 · UNKNOWN · sponsor: **HRYZ Biotech Co.** · enrollment: 17 (estimated)

## Conditions studied

- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma
- Oropharyngeal Cancer
- Vagina Tumor
- Carcinoma of Penis
- Anal Carcinoma
- Carcinoma of Vulva

## Interventions

- **DRUG:** Fludarabine + Cyclophosphamide
- **BIOLOGICAL:** HRYZ-T101 TCR-T Cell

## Key facts

- **NCT ID:** NCT05787535
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-21
- **Primary completion:** 2025-02
- **Final completion:** 2025-09
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787535, "HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05787535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*